FORM 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  Gaston-Dreyfus Remi
2. Date of Event Requiring Statement (Month/Day/Year)
09/01/2017
3. Issuer Name and Ticker or Trading Symbol
Bionik Laboratories Corp. [BNKL]
(Last)
(First)
(Middle)
46 RUE PIERRE CHARRON
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

PARIS, I0 75008
6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(Month/Day/Year)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy)   (1) 12/14/2022 Common Stock 250,000 $ 1 D  
Exchangeable Shares   (2)   (2) Common Stock 2,621,362 $ 0 I Shares held through Lombard International Assurance SA.
Exchangeable Shares   (3)   (3) Common Stock 749,529 $ 0 I Shares held through a French SAS holding company named RGD Investissements.

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Gaston-Dreyfus Remi
46 RUE PIERRE CHARRON
PARIS, I0 75008
  X      

Signatures

/s/ Joel Rubinstein, Attorney-in-Fact 09/11/2017
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) The stock options were granted on December 14, 2015 and vest in three substantially equal annual installments on each of the first three anniversaries of the grant date.
(2) Represents 2,621,362 exchangeable shares that are convertible into shares of common stock of the Issuer on a one-for-one basis. The exchangeable shares are currently exercisable and have no expiration date. The exchangeable shares are held by Lombard International Assurance SA.
(3) Represents 749,529 exchangeable shares that are convertible into shares of common stock of the Issuer on a one-for-one basis. The exchangeable shares are currently exercisable and have no expiration date. The exchangeable shares are held by RGD Investissements.
 
Remarks:
See Exhibit 24.1 - Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.